Terns Pharmaceuticals Net Worth
Terns Pharmaceuticals Net Worth Breakdown | TERN |
Terns Pharmaceuticals Net Worth Analysis
Terns Pharmaceuticals' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Terns Pharmaceuticals' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Terns Pharmaceuticals' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Terns Pharmaceuticals' net worth analysis. One common approach is to calculate Terns Pharmaceuticals' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Terns Pharmaceuticals' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Terns Pharmaceuticals' net worth. This approach calculates the present value of Terns Pharmaceuticals' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Terns Pharmaceuticals' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Terns Pharmaceuticals' net worth. This involves comparing Terns Pharmaceuticals' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Terns Pharmaceuticals' net worth relative to its peers.
Enterprise Value |
|
To determine if Terns Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Terns Pharmaceuticals' net worth research are outlined below:
| Terns Pharmaceuticals generated a negative expected return over the last 90 days | |
| Terns Pharmaceuticals has high historical volatility and very poor performance | |
| Terns Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (90.21 M) with profit before overhead, payroll, taxes, and interest of 1000 K. | |
| Terns Pharmaceuticals currently holds about 139.81 M in cash with (67.39 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.51. | |
| Terns Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Terns Pharmaceuticals Stock Drops Over 5 percent Amidst Mixed Industry Performance |
Terns Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Terns Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Terns Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 25th of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 25th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Terns Pharmaceuticals Target Price Consensus
Terns target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Terns Pharmaceuticals' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 9 | Strong Buy |
Most Terns analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Terns stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Terns Pharmaceuticals, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationTerns Pharmaceuticals Target Price Projection
Terns Pharmaceuticals' current and average target prices are 5.71 and 16.63, respectively. The current price of Terns Pharmaceuticals is the price at which Terns Pharmaceuticals is currently trading. On the other hand, Terns Pharmaceuticals' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Terns Pharmaceuticals Market Quote on 22nd of November 2024
Target Price
Analyst Consensus On Terns Pharmaceuticals Target Price
Know Terns Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Terns Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Terns Pharmaceuticals backward and forwards among themselves. Terns Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Terns Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Octagon Capital Advisors Lp | 2024-06-30 | 1.4 M | State Street Corp | 2024-06-30 | 1.2 M | Fmr Inc | 2024-09-30 | 1.2 M | Great Point Partners Llc | 2024-06-30 | 1.1 M | Millennium Management Llc | 2024-06-30 | 1.1 M | Franklin Resources Inc | 2024-06-30 | 1.1 M | Geode Capital Management, Llc | 2024-06-30 | 1.1 M | Driehaus Capital Management Llc | 2024-06-30 | 1.1 M | Bellevue Group Ag | 2024-09-30 | 1 M | Orbimed Advisors, Llc | 2024-06-30 | 7.6 M | Vivo Capital, Llc | 2024-09-30 | 6.9 M |
Follow Terns Pharmaceuticals' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 475.66 M.Market Cap |
|
Project Terns Pharmaceuticals' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.34) | (0.35) | |
| Return On Capital Employed | (0.40) | (0.42) | |
| Return On Assets | (0.34) | (0.35) | |
| Return On Equity | (0.35) | (0.37) |
When accessing Terns Pharmaceuticals' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Terns Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Terns Pharmaceuticals' profitability and make more informed investment decisions.
Evaluate Terns Pharmaceuticals' management efficiency
Terns Pharmaceuticals has return on total asset (ROA) of (0.1923) % which means that it has lost $0.1923 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2828) %, meaning that it created substantial loss on money invested by shareholders. Terns Pharmaceuticals' management efficiency ratios could be used to measure how well Terns Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of the 22nd of November 2024, Return On Tangible Assets is likely to drop to -0.35. In addition to that, Return On Capital Employed is likely to drop to -0.42. At this time, Terns Pharmaceuticals' Net Tangible Assets are very stable compared to the past year. As of the 22nd of November 2024, Non Current Assets Total is likely to grow to about 1.4 M, while Total Assets are likely to drop about 170.3 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.58 | 3.14 | |
| Tangible Book Value Per Share | 3.58 | 3.14 | |
| Enterprise Value Over EBITDA | (3.75) | (3.93) | |
| Price Book Value Ratio | 1.81 | 1.72 | |
| Enterprise Value Multiple | (3.75) | (3.93) | |
| Price Fair Value | 1.81 | 1.72 | |
| Enterprise Value | 258.5 M | 343.9 M |
The strategic initiatives led by Terns Pharmaceuticals' management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Enterprise Value Revenue 337.4686 | Revenue 1000 K | Revenue Per Share 0.035 | Return On Equity (0.28) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Terns Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Terns Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Terns Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Terns Pharmaceuticals Corporate Filings
F3 | 19th of November 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
8K | 18th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 8th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
Terns Pharmaceuticals Earnings Estimation Breakdown
The calculation of Terns Pharmaceuticals' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Terns Pharmaceuticals is estimated to be -0.29875 with the future projection ranging from a low of -0.3125 to a high of -0.2825. Please be aware that this consensus of annual earnings estimates for Terns Pharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.31 Lowest | Expected EPS | -0.28 Highest |
Terns Pharmaceuticals Earnings Projection Consensus
Suppose the current estimates of Terns Pharmaceuticals' value are higher than the current market price of the Terns Pharmaceuticals stock. In this case, investors may conclude that Terns Pharmaceuticals is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Terns Pharmaceuticals' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2024 | Current EPS (TTM) | |
| 9 | 82.08% | -0.28 | -0.29875 | -1.18 |
Terns Pharmaceuticals Earnings per Share Projection vs Actual
Actual Earning per Share of Terns Pharmaceuticals refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Terns Pharmaceuticals predict the company's earnings will be in the future. The higher the earnings per share of Terns Pharmaceuticals, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Terns Pharmaceuticals Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Terns Pharmaceuticals, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Terns Pharmaceuticals should always be considered in relation to other companies to make a more educated investment decision.Terns Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Terns Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-12 | 2024-09-30 | -0.32 | -0.28 | 0.04 | 12 | ||
2024-08-05 | 2024-06-30 | -0.34 | -0.31 | 0.03 | 8 | ||
2024-05-13 | 2024-03-31 | -0.34 | -0.3 | 0.04 | 11 | ||
2024-03-14 | 2023-12-31 | -0.29 | -0.29 | 0.0 | 0 | ||
2023-11-14 | 2023-09-30 | -0.31 | -0.42 | -0.11 | 35 | ||
2023-08-08 | 2023-06-30 | -0.34 | -0.25 | 0.09 | 26 | ||
2023-05-15 | 2023-03-31 | -0.27 | -0.31 | -0.04 | 14 | ||
2023-03-27 | 2022-12-31 | -0.43 | -0.29 | 0.14 | 32 | ||
2022-11-09 | 2022-09-30 | -0.52 | -0.44 | 0.08 | 15 | ||
2022-08-08 | 2022-06-30 | -0.59 | -0.55 | 0.04 | 6 | ||
2022-05-16 | 2022-03-31 | -0.64 | -0.55 | 0.09 | 14 | ||
2022-03-03 | 2021-12-31 | -0.63 | -0.56 | 0.07 | 11 | ||
2021-11-15 | 2021-09-30 | -0.6 | -0.47 | 0.13 | 21 | ||
2021-08-16 | 2021-06-30 | -0.71 | -0.43 | 0.28 | 39 | ||
2021-05-14 | 2021-03-31 | -0.77 | -0.88 | -0.11 | 14 | ||
2021-03-30 | 2020-12-31 | -0.91 | -30.94 | -30.03 | 3300 |
Terns Pharmaceuticals Corporate Management
| David Strauss | VP Controller | Profile | |
| Pamela Danagher | Senior Assurance | Profile | |
| Debra Sieminski | Senior Affairs | Profile | |
| Jeffrey Jasper | Senior Research | Profile | |
| JD Esq | Chief Officer | Profile | |
| Senthil Sundaram | CEO Director | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Terns Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Terns Stock, please use our How to Invest in Terns Pharmaceuticals guide.You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Terns Pharmaceuticals. If investors know Terns will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Terns Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.18) | Revenue Per Share 0.035 | Return On Assets (0.19) | Return On Equity (0.28) |
The market value of Terns Pharmaceuticals is measured differently than its book value, which is the value of Terns that is recorded on the company's balance sheet. Investors also form their own opinion of Terns Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Terns Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Terns Pharmaceuticals' market value can be influenced by many factors that don't directly affect Terns Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Terns Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Terns Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Terns Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.